

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this joint announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this joint announcement.

This joint announcement appears for information purposes only and is not intended to and does not constitute, or form part of, any offer to purchase or subscribe for or an invitation to purchase or subscribe for any securities of the Offeror or the Company or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities of the Company in any jurisdiction in contravention of applicable law.



Grand Full Development Limited
(創隆發展有限公司)
*(Incorporated in Hong Kong with
limited liability)*

**Bloomage BioTechnology
Corporation Limited**
華熙生物科技有限公司
*(Incorporated in the Cayman Islands
with limited liability)*
(Stock Code: 00963)

JOINT ANNOUNCEMENT

**PROPOSAL FOR THE PRIVATISATION OF
BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED
BY
GRAND FULL DEVELOPMENT LIMITED
BY WAY OF A SCHEME OF ARRANGEMENT
(UNDER SECTION 86 OF THE COMPANIES LAW)**

- (1) SANCTION OF THE SCHEME BY THE GRAND COURT
AND
(2) PROPOSED WITHDRAWAL OF LISTING**

Financial Adviser to the Offeror



華泰金融控股(香港)有限公司
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED

References are made to the scheme document jointly issued by Bloomage BioTechnology Corporation Limited (the “**Company**”) and Grand Full Development Limited (the “**Offeror**”) on 15 September 2017 in relation to the proposed privatization of the Company by way of a scheme of arrangement under Section 86 of the Companies Law (the “**Scheme Document**”) and the joint announcement issued by the Company and the Offeror on 16 October 2017 in relation to the results of the Court Meeting and the EGM (the “**Results Announcement**”).

Unless otherwise defined, terms used herein shall have the same meaning as those defined in the Scheme Document.

SANCTION OF THE SCHEME AND CONFIRMATION OF THE CAPITAL REDUCTION BY THE GRAND COURT

The Scheme was sanctioned without modification by the Grand Court on Friday, 27 October 2017 (Cayman Islands time). The reduction of the issued share capital of the Company resulting from the cancellation and extinguishment of the Scheme Shares was also confirmed by the Grand Court on the same day.

A copy of the order of the Grand Court sanctioning the Scheme and confirming the reduction of the issued share capital of the Company is expected to be delivered to the Registrar of Companies in the Cayman Islands for registration on Monday, 30 October 2017 (Cayman Islands time). Notice of the registration shall be published in the Cayman Islands Gazette and in a Hong Kong newspaper in English and a Hong Kong newspaper in Chinese within 21 days of such registration.

EXPECTED EFFECTIVE DATE

All of the Conditions as set out on pages 56 to 58 of the Scheme Document in the section headed “4. Conditions of the Proposal and the Scheme” in the Explanatory Memorandum have been fulfilled, except for the delivery to the Registrar of Companies in the Cayman Islands of a copy of the order of the Grand Court for registration, which is expected to be completed by Monday, 30 October 2017 (Cayman Islands time). As such, the Scheme is expected to become effective on Monday, 30 October 2017 (Cayman Islands time).

A further announcement will be made when the Scheme has become effective.

PROPOSED WITHDRAWAL OF LISTING

As part of the Proposal, and upon the Scheme becoming effective, it is expected that the listing of the Shares on the Stock Exchange will be withdrawn at or before 4:00 p.m. on Wednesday, 1 November 2017 (Hong Kong time).

ZHAO SHARES

As part of the Proposal, and upon the Scheme becoming effective, Ms. Zhao will surrender the Zhao Shares for cancellation and the Company will allot and issue to the Offeror such number of new Shares as is equal to the number of the Zhao Shares surrendered and cancelled.

TERMINATION OF THE OPTION AGREEMENT

As part of the Proposal, and upon the Scheme having become effective, the Option Agreement shall also terminate pursuant to the terms of the Termination Agreement and the Termination Fee shall be payable by AIM First to Wealthy Delight.

GENERAL

For further information in respect of the timetable of the Scheme, please refer to the remaining expected events and the corresponding dates and times in the section headed “Expected Timetable” in the Results Announcement.

WARNINGS

Shareholders, Optionholders and potential investors should be aware that the implementation of the Proposal, the Scheme and the Option Offer are subject to the Conditions being fulfilled or waived, as applicable, and thus the Proposal may or may not be implemented, the Scheme may or may not become effective and the Option Offer may or may not be implemented. Shareholders, Optionholders and potential investors should therefore exercise caution when dealing in the securities of the Company. Persons who are in doubt as to the action they should take should consult their stockbroker, bank manager, solicitor or other professional advisers.

The Offeror and the Company hereby remind their respective associates of the dealing restrictions under the Takeovers Code and to disclose their permitted dealings, if any, in any securities of the Company.

By Order of the board of
Grand Full Development Limited
創隆發展有限公司
Zhao Yan
Director

By Order of the board of
Bloomage BioTechnology Corporation
Limited
華熙生物科技股份有限公司
Gong Anmin
Director

Hong Kong, 30 October 2017

As at the date of this joint announcement, the sole director of the Offeror is Ms. Zhao.

The sole director of the Offeror accepts full responsibility for the accuracy of the information contained in this joint announcement (other than that relating to the Group) and confirm, having made all reasonable enquiries, that to the best of her knowledge, opinions expressed in this joint announcement (other than those expressed by the Group) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statement in this joint announcement misleading.

As at the date of this joint announcement, the Directors are:

Executive Directors:

Ms. Zhao Yan

Mr. Jin Xuekun

Mr. Gong Anmin

Ms. Wang Aihua

Non-executive Director:

Mr. Yau Wai Yan

*Independent non-executive
Directors:*

Ms. Zhan Lili

Mr. Li Junhong

Mr. Xue Zhaofeng

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this joint announcement (other than that relating to the Offeror) and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this joint announcement (other than those expressed by the Offeror) having been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statement in this joint announcement misleading.